Meeting
2022 ASCO Gastrointestinal Cancers Symposium
A phase I study of first-line L-glutamine (Gln) with gemcitabine (gem) and nab-paclitaxel (nab-p) in advanced pancreatic cancer (GlutaPanc).
Authors
John Davelaar
Cedars-Sinai Medical Center, Los Angeles, CA
John Davelaar , Mourad Tighiouart , Andrew Eugene Hendifar , Arsen Osipov , Natalie Moshayedi , Veronica Placencio-Hickok , Neil Bhowmick , Jun Gong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Translational Research
Clinical Trial Registration Number
NCT04634539
DOI
10.1200/JCO.2022.40.4_suppl.TPS636
Abstract #
TPS636
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Nab-paclitaxel (nab-P) combined with FOLFOX for advanced pancreatic cancer: A phase I study.
First Author: Howard Safran
Poster
2014 Gastrointestinal Cancers Symposium
FOLFOX and nab-paclitaxel (nab-P) for advanced pancreatic cancer: A phase I study.
First Author: Howard Safran
Poster
2023 ASCO Annual Meeting
FOOTPATH: A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC).
First Author: Benedikt Westphalen
Poster
2023 ASCO Gastrointestinal Cancers Symposium
First-line chemotherapy regimens associated with survival in advanced pancreatic cancer: A Mexican single-center, real-world study.
First Author: Marytere Herrera